Innate Pharma S.A.
IPHA
Rank in Stocks
#17557
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Share Price
$1.51
Last synced: 2026-11-09
Market Cap
$163.72M
Change (1 day)
4.86%
Change (1 year)
-29.44%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Innate Pharma S.A. (IPHA)
Category
Healthcare
EPS for Innate Pharma S.A. (IPHA)
EPS as of June 2026 TTM: $-0.57
According to Innate Pharma S.A.'s latest financial reports, its current EPS (TTM) is $-0.57. At the end of 2025 the company had an EPS of $-0.62, an increase over its 2024 EPS of $-0.63.
EPS history for Innate Pharma S.A. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.57 | -8.27% |
| 2025 | $-0.62 | -2.03% |
| 2024 | $-0.63 | 537.89% |
| 2023 | $-0.10 | -87.29% |
| 2022 | $-0.78 | 20.81% |
| 2021 | $-0.65 | 4,964.06% |
| 2020 | $-0.01 | -96.32% |
| 2019 | $-0.35 | -683.56% |
| 2018 | $0.06 | -105.58% |
| 2017 | $-1.07 | -541.28% |
| 2016 | $0.24 | -271.39% |
| 2015 | $-0.14 | -70.08% |
| 2014 | $-0.47 | 359.49% |
| 2013 | $-0.10 | -7.97% |
| 2012 | $-0.11 | -54.63% |
| 2011 | $-0.25 | -48.89% |
| 2010 | $-0.48 | -40.06% |
| 2009 | $-0.80 | 51.62% |
| 2008 | $-0.53 | 0.65% |
| 2007 | $-0.53 | 17.61% |
| 2006 | $-0.45 | -7.64% |
| 2005 | $-0.48 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,853.65% |
US
|
|
| $-7.07 | 1,143.19% |
US
|
|
| $-5.29 | 830.19% |
AU
|
|
| $12.88 | -2,364.83% |
BE
|
|
| $21.56 | -3,891.10% |
NL
|
Questions about Innate Pharma S.A.'s earnings per share (EPS)
What is Innate Pharma S.A.'s earnings per share (EPS)?
Innate Pharma S.A.'s earnings per share (EPS) over the last twelve months is $-0.57, as of Jun 2026.
What was Innate Pharma S.A.'s earnings per share (EPS) in 2025?
In 2025, Innate Pharma S.A.'s earnings per share (EPS) was $-0.62, compared with $-0.63 in 2024.
How has Innate Pharma S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Innate Pharma S.A.'s earnings per share (EPS) was highest in 2020 ($-0.01) and lowest in 2022 ($-0.78).
How does Innate Pharma S.A.'s earnings per share (EPS) compare with similar companies?
Innate Pharma S.A.'s earnings per share (EPS) ($-0.57) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.